Veteran broadcaster Jane King from the NASDAQ MarketSite in Times Square interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals, discussing NRx-101 – the first investigational drug in FDA trials for suicidal bipolar depression.
Jonathan Javitt
Nov. 20, 2023
Jane King, NASDAQ MarketSite interviews Jonathan C. Javitt, M.D., M.P.H./Chief Scientist, Director, and Founder, NRx Pharmaceuticals
Nov. 8, 2022
NRx Pharmaceuticals Chief Scientist, Dr. Jonathan C. Javitt on Bipolar Depression With Suicidality
See our Chief Scientist, Dr. Jonathan C. Javitt, provide a comprehensive description on why we are committed to solve for a very high unmet need in bipolar depression with suicidality.
Aug. 1, 2022
Scientific Update from NRx Pharmaceuticals Chief Scientist, Jonathan Javitt, MD, MPH
In light of recent findings related to serotonin and its role in depression, investors have asked us to provide more specific information on the primary target addressed by D-cycloserine, a component of NRX-101.
- 1
- 2